Portfoliotracker

Hansa Biopharma AB (publ)

HNSA.ST · STOCKHOLM · Healthcare Biotechnology 1/100 E

48,78 SEK
▼ −0,78 (−1,57 %)
Trading
Price as of 17. 11. 14:21, fetched 17. 11. 14:21
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score1 / 100 Market cap5,04 mld. SEK P/E– Forward P/E-6,7 P/S26,6 P/B– EV/EBITDA– Dividend yield– FCF yield-11,20 % EPS-7,86 SEK Net margin-260,4 % Return on equity– Beta– Debt / equity–
52-week range 23,52 to 51,65
3-month average volume0,6 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD) and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was formerly known as Hansa Medical AB (publ) and changed its name to Hansa Biopharma AB (publ) in December 2018. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Employees
125
Country
Sweden
Data since
17. 10. 2007

Explore further

Similar companies ONCO.STBINV.STSANION.ST

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account